Evidence map›Paper›PMID 33935016›Full record

ArticleClinical colorectal cancer2021

Fusobacterium nucleatum and Clinicopathologic Features of Colorectal Cancer: Results From the ColoCare Study.

Yannick Eisele, Patrick M Mallea, Biljana Gigic, W Zac Stephens, Christy A Warby, Kate Buhrke, Tengda Lin, Juergen Boehm, Petra Schrotz-King, Sheetal Hardikar and 22 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Clinical colorectal cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328677 recruitingnot on this map

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

TypeobservationalSponsorUniversity of UtahRan2007 to 2030Enrolled5,000ConditionsColorectal Cancer
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Medicina (Kaunas, Lithuania) · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Association ofGut microbiome (Cambridge, England) · 2025
    Review
  12. Review
  13. Potential and application ofFrontiers in microbiology · 2025
    Article
  14. Evaluation of Periodontitis andHealthcare (Basel, Switzerland) · 2024
    Article
  15. Article
  16. Application ofWorld journal of gastrointestinal oncology · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 10 institutions in 2 countries.

Yannick EiseleHuntsman Cancer Institute, Salt Lake City, UT; Department of Population Health Sciences, University of Utah, Salt Lake City, UT; Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Patrick M MalleaHuntsman Cancer Institute, Salt Lake City, UT; Department of Population Health Sciences, University of Utah, Salt Lake City, UT.
Biljana GigicDepartment of General, Visceral and Transplantation Surgery, University Hospital of Heidelberg, Heidelberg, Germany.
W Zac StephensDepartment of Pathology, University of Utah, Salt Lake City, UT.
Christy A WarbyHuntsman Cancer Institute, Salt Lake City, UT; Department of Population Health Sciences, University of Utah, Salt Lake City, UT.
Kate BuhrkeDepartment of Pathology, University of Utah, Salt Lake City, UT.
Tengda LinHuntsman Cancer Institute, Salt Lake City, UT; Department of Population Health Sciences, University of Utah, Salt Lake City, UT.
Juergen BoehmHuntsman Cancer Institute, Salt Lake City, UT; Department of Population Health Sciences, University of Utah, Salt Lake City, UT.
Petra Schrotz-KingDivision of Preventive Oncology, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.
Sheetal HardikarHuntsman Cancer Institute, Salt Lake City, UT; Department of Population Health Sciences, University of Utah, Salt Lake City, UT.
Lyen C HuangDivision of General Surgery, Department of Surgery, School of Medicine, University of Utah, Salt Lake City, UT.
T Bartley PickronDivision of General Surgery, Department of Surgery, School of Medicine, University of Utah, Salt Lake City, UT.
Courtney L ScaifeDivision of General Surgery, Department of Surgery, School of Medicine, University of Utah, Salt Lake City, UT.
Richard ViskochilHuntsman Cancer Institute, Salt Lake City, UT; Department of Population Health Sciences, University of Utah, Salt Lake City, UT.
Torsten KoelschDepartment of General, Visceral and Transplantation Surgery, University Hospital of Heidelberg, Heidelberg, Germany.
Anita R PeoplesHuntsman Cancer Institute, Salt Lake City, UT; Department of Population Health Sciences, University of Utah, Salt Lake City, UT.
Maria A PletnevaHuntsman Cancer Institute, Salt Lake City, UT; Department of Pathology, University of Utah, Salt Lake City, UT.
Mary BronnerHuntsman Cancer Institute, Salt Lake City, UT; Department of Pathology, University of Utah, Salt Lake City, UT.
Martin SchneiderDepartment of General, Visceral and Transplantation Surgery, University Hospital of Heidelberg, Heidelberg, Germany.
Alexis B UlrichDepartment of General, Visceral and Transplantation Surgery, University Hospital of Heidelberg, Heidelberg, Germany.
Eric A SwansonDepartment of Pathology, University of Utah, Salt Lake City, UT.
Adetunji T ToriolaWashington University in St. Louis, St. Louis, MO.
David ShibataDepartment of Surgery, University of Tennessee Health Science Center, Memphis, TN.
Christopher I LiPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Erin M SiegelCancer Epidemiology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Jane FigueiredoSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Klaus-Peter JanssenKlinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany; Department of Surgery, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.
Hans HaunerKlinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany; Else Kröner-Fresenius-Centre for Nutritional Medicine, School of Life Sciences, Technical University of Munich, Munich, Germany.
June RoundDepartment of Pathology, University of Utah, Salt Lake City, UT.
Cornelia M UlrichHuntsman Cancer Institute, Salt Lake City, UT; Department of Population Health Sciences, University of Utah, Salt Lake City, UT.
Andreana N HolowatyjHuntsman Cancer Institute, Salt Lake City, UT; Department of Population Health Sciences, University of Utah, Salt Lake City, UT; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Vanderbilt-Ingram Cancer Center, Nashville, TN. Electronic address: andreana.holowatyj@vumc.org.
Jennifer OseHuntsman Cancer Institute, Salt Lake City, UT; Department of Population Health Sciences, University of Utah, Salt Lake City, UT. Electronic address: jennifer.ose@hci.utah.edu.
Huntsman Cancer Institute · USUniversity of Utah · USHeidelberg University · DETUM Klinikum · DECedars-Sinai Medical Center · USFred Hutch Cancer Center · USGerman Cancer Research Center · DEMoffitt Cancer Center · USUniversity of Tennessee Health Science Center · USWashington University in St. Louis · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6M
Building Interdisciplinary Research Careers in Women's HealthK12HD043483 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARTMANN, KATHERINE E, MAJOR, AMY S · 2002 to 2023
$10.3M
Discovery and verification of novel biomarkers of colorectal cancer recurrenceR01CA189184 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2015 to 2020
$5.6M
Vascular Health and Risk Factors in Children with Down SyndromeKL2TR002539 · NCATS · UNIVERSITY OF UTAH · PI MURTAUGH, MAUREEN A, NYGAARD, INGRID E · 2018 to 2022
$4.3M
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer RecurrenceR01CA207371 · NCI · UNIVERSITY OF UTAH · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2017 to 2022
$3.9M
Training Program in Genomic MedicineT32HG008962 · NHGRI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Lynn Jorde, Aaron R Quinlan · 2016 to 2026
$3.0M
Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP StudyR01CA211705 · NCI · UNIVERSITY OF UTAH · PI LASTAYO, PAUL C, ULRICH, CORNELIA M · 2017 to 2021
$2.2M
Diabetes, Medications and the Cost-Effectiveness of Screening for Colorectal NeoplasiaK07CA222060 · NCI · UNIVERSITY OF UTAH · PI HARDIKAR, SHEETAL · 2018 to 2022
$791k
NCATS NIH HHS KL2 TR002539NCATS NIH HHS UL1 TR002538NCI NIH HHS K07 CA222060NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA207371NCI NIH HHS R01 CA211705NCI NIH HHS U01 CA206110NHGRI NIH HHS T32 HG008962NICHD NIH HHS K12 HD043483
6 · The paper itself

Abstract

backgroundFusobacterium nucleatum (Fn), a bacterium associated with a wide spectrum of infections, has emerged as a key microbe in colorectal carcinogenesis. However, the underlying mechanisms and clinical relevance of Fn in colorectal cancer (CRC) remain incompletely understood. PATIENTS AND

methodsWe examined associations between Fn abundance and clinicopathologic characteristics among 105 treatment-naïve CRC patients enrolled in the international, prospective ColoCare Study. Electronic medical charts, including pathological reports, were reviewed to document clinicopathologic features. Quantitative real-time polymerase chain reaction (PCR) was used to amplify/detect Fn DNA in preoperative fecal samples. Multinomial logistic regression was used to analyze associations between Fn abundance and patient sex, age, tumor stage, grade, site, microsatellite instability, body mass index (BMI), alcohol consumption, and smoking history. Cox proportional hazards models were used to investigate associations of Fn abundance with overall survival in adjusted models.

resultsCompared to patients with undetectable or low Fn abundance, patients with high Fn abundance (n = 22) were 3-fold more likely to be diagnosed with rectal versus colon cancer (odds ratio [OR] = 3.01; 95% confidence interval [CI], 1.06-8.57; P = .04) after adjustment for patient sex, age, BMI, and study site. Patients with high Fn abundance also had a 5-fold increased risk of being diagnosed with rectal cancer versus right-sided colon cancer (OR = 5.32; 95% CI, 1.23-22.98; P = .03). There was no statistically significant association between Fn abundance and overall survival.

conclusionOur findings suggest that Fn abundance in fecal samples collected prior to surgery varies by tumor site among treatment-naïve CRC patients. Overall, fecal Fn abundance may have diagnostic and prognostic significance in the clinical management of CRC.

Indexed as

Colorectal NeoplasmsFusobacterium nucleatumHumansMicrosatellite InstabilityPrognosisProspective StudiesFusobacteriumgut microbiomerectal cancerstooltumor site

Identifiers

PMID33935016
PMCPMC8390557
OpenAlexW3134949351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.